Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 125

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 125
---
 to enhance our sales, marketing and customer support capabilities, which will involve developing and administering our commercial infrastructure and/or collaborative commercial arrangements and partnerships. If we are unable to develop commercial infrastructure and enter into commercial agreements, then our business would be adversely affected. We currently have such arrangements with CIBIC as our exclusive agent in Argentina for the commercialization of our analyses, delegating operational phases while retaining intellectual property. Further, pursuant to the Commercialization 37 Agreement, CIBIC provides sample processing services to support our analyses, in accordance with our specifications and quality standards. Additionally, we currently have arrangements with Meyer in Paraguay to provide our clinical genetic diagnostic tests and results. The agreement with CIBIC is valid for 30 years from the signing date and will be automatically renewed for ten -yearperiods unless terminated with proper notice. We must also maintain satisfactory arrangements for the manufacture and distribution of our tests and operate certified lab facilities to process our tests and provide patient results. Failure to augment our operational resources organically or through collaborations with third parties may have an adverse impact on our business, financial condition, results of operations and growth prospects. Potential changes in our leadership could adversely affect our business. Our success depends in large part on the skill, experience, and performance of our executive management team and others in key leadership positions. The continued efforts of these persons will be critical to us as we continue to develop our technologies and focus on growing our business. If we lose one or more of these key executives, we could experience difficulties maintaining our operations, including our ability to compete effectively, advance our technologies, develop new tests and implement our business strategies. Such changes in our executive management, and any future changes, as well as the effects of our business realignment, could also disrupt our business, and could impact our ability to preserve our culture, which could negatively affect our ability to recruit and retain personnel. Further, these changes may also increase our dependency on other members of our executive team. If we lose the services of any member of the executive management team or any key personnel, we may not be able to secure a suitable or qualified replacement, which could disrupt our business and could be particularly disruptive considering our strategic realignment in connection with the Business Combination. We rely on highly skilled personnel in a broad array of disciplines and, if we are unable to attract and retain additional qualified personnel, we may not be able to maintain the quality of our tests and services or grow effectively. Our business, including our research and development programs and laboratory operations, largely depend on our